← All Sponsors
SPONSOR

Shanghai SciBrunch Therapeutics Co., Ltd.

Total Trials
1
Recruiting
1
Phases
Phase 1, Phase 2
Conditions studied: Advanced Solid TumorsPARP Inhibitor
NCT07359066 Phase 1, Phase 2
Recruiting

An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
China View Trial →